Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
27.53
-0.86 (-3.03%)
At close: Jul 17, 2026, 4:00 PM EDT
28.34
+0.81 (2.94%)
After-hours: Jul 17, 2026, 7:34 PM EDT
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $31.74M in the quarter ending March 31, 2026, with 324.87% growth. This brings the company's revenue in the last twelve months to $164.01M, up 157.97% year-over-year. In the year 2025, Beam Therapeutics had annual revenue of $139.74M with 120.01% growth.
Revenue (ttm)
$164.01M
Revenue Growth
+157.97%
P/S Ratio
16.71
Revenue / Employee
$314,197
Employees
522
Market Cap
2.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 139.74M | 76.23M | 120.01% |
| Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
| Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
| Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
| Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
| Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
| Dec 31, 2019 | 18.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| Tarsus Pharmaceuticals | 535.08M |
| uniQure | 18.09M |
| AtaiBeckley | 3.49M |
| Celldex Therapeutics | 865.00K |
BEAM News
- 9 days ago - TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647 - TheFly
- 9 days ago - Resolution in favor of Prime has limited impact to Beam, says BofA - TheFly
- 9 days ago - Prime Medicine reports positive resolution to arbitration with Beam Therapeutics - TheFly
- 4 weeks ago - Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304 - TheFly
- 4 weeks ago - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration - GlobeNewsWire
- 4 weeks ago - The Healthcare M&A Wave - Forbes
- 6 weeks ago - Beam Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts